Raymond James Financial
CRDF icon

Raymond James Financial’s Cardiff Oncology CRDF Stock Holding History

Raymond James Financial’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.7K Sell
22,672
-4,000
-15% -$8.21K ﹤0.01% 5152
2025
Q4 		$74.9K Buy
26,672
+3,040
+13% +$7.06K ﹤0.01% 4969
2025
Q3 		$48.7K Buy
23,632
+9,740
+70% +$26.9K ﹤0.01% 4829
2025
Q2 		$43.8K Buy
13,892
+1,417
+11% +$4.32K ﹤0.01% 5238
2025
Q1 		$39.2K Sell
12,475
-521
-4% -$2.06K ﹤0.01% 4657
2024
Q4 		$56.4K Buy
+12,996
New +$40.6K ﹤0.01% 4595

Other funds holding CRDF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return

Raymond James Financial's CRDF Position: Q1 2026 in Review

Raymond James Financial reduced its Cardiff Oncology (CRDF) stake by 15% in Q1 2026, selling an estimated $8.21K and leaving 22,672 shares worth $36.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5152.

Raymond James Financial first reported a position in CRDF in Q4 2024 and has held it in 6 quarters since. The position peaked at $74.9K in Q4 2025. 117 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Raymond James Financial held 22,672 shares of Cardiff Oncology worth $36.7K as of Q1 2026.
  • Raymond James Financial sold 4,000 Cardiff Oncology shares in Q1 2026, an estimated $8.21K.
  • Cardiff Oncology made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5152 holding.
  • Raymond James Financial first reported a position in Cardiff Oncology in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Cardiff Oncology position peaked at $74.9K in Q4 2025.
  • 117 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.